These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24084704)

  • 1. Molecular imaging of prostate cancer with PET.
    Jadvar H
    J Nucl Med; 2013 Oct; 54(10):1685-8. PubMed ID: 24084704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.
    Jadvar H
    J Nucl Med; 2016 Oct; 57(Suppl 3):25S-29S. PubMed ID: 27694167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Imaging of Prostate Cancer.
    Wibmer AG; Burger IA; Sala E; Hricak H; Weber WA; Vargas HA
    Radiographics; 2016; 36(1):142-59. PubMed ID: 26587888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bombesin-Targeted PET of Prostate Cancer.
    Mansi R; Minamimoto R; Mäcke H; Iagaru AH
    J Nucl Med; 2016 Oct; 57(Suppl 3):67S-72S. PubMed ID: 27694175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
    Hope TA; Aggarwal RR; Westphalen AC; Cooperberg MR; Greene KL
    Future Oncol; 2016 Nov; 12(21):2393-2396. PubMed ID: 27453303
    [No Abstract]   [Full Text] [Related]  

  • 7. [Positron emission tomography for molecular imaging of prostate cancer].
    Shen GH; Zhang WJ; Jia ZY; Deng HF
    Zhonghua Nan Ke Xue; 2014 Nov; 20(11):1039-42. PubMed ID: 25577843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of prostate cancer: PET radiotracers.
    Jadvar H
    AJR Am J Roentgenol; 2012 Aug; 199(2):278-91. PubMed ID: 22826388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Imaging and Precision Medicine in Prostate Cancer.
    Ceci F; Fiorentino M; Castellucci P; Fanti S
    PET Clin; 2017 Jan; 12(1):83-92. PubMed ID: 27863569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
    Schuster DM; Nanni C; Fanti S
    J Nucl Med; 2016 Oct; 57(Suppl 3):61S-66S. PubMed ID: 27694174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
    Gorin MA; Rowe SP; Denmeade SR
    PET Clin; 2017 Apr; 12(2):185-192. PubMed ID: 28267452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear medicine studies of the prostate, testes, and bladder.
    Jana S; Blaufox MD
    Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results.
    Franc BL; Cho SY; Rosenthal SA; Cui Y; Tsui B; Vandewalker KM; Holz AL; Poonamallee U; Pomper MG; James RB
    Eur J Radiol; 2013 Nov; 82(11):1877-84. PubMed ID: 23993140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?
    Basu B; Basu S
    Cancer Biother Radiopharm; 2016 Apr; 31(3):75-84. PubMed ID: 27093341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].
    Cochet A; Kanoun S; Humbert O; Walker PM; Cormier L; Créhange G; Brunotte F
    Cancer Radiother; 2014 Oct; 18(5-6):509-16. PubMed ID: 25195114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.
    Lindenberg ML; Turkbey B; Mena E; Choyke PL
    JAMA Oncol; 2017 Oct; 3(10):1415-1422. PubMed ID: 28097325
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Chakravarty R; Chakraborty S; Dash A
    Mol Pharm; 2016 Nov; 13(11):3601-3612. PubMed ID: 27709959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
    Glumac PM; Gallant JP; Shapovalova M; Li Y; Murugan P; Gupta S; Coleman IM; Nelson PS; Dehm SM; LeBeau AM
    Clin Cancer Res; 2020 Mar; 26(5):1054-1064. PubMed ID: 31732520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Prostate Cancer with 11C-Acetate PET/CT.
    Spick C; Herrmann K; Czernin J
    J Nucl Med; 2016 Oct; 57(Suppl 3):30S-37S. PubMed ID: 27694168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.